Get more info on this report!The Worldwide Market for Anti-Infectives (Antifungals, Antibacte...
The information for this report was gathered using both primary and secondary researchincluding comprehensive research of ...
CHAPTER THREE: ANTIFUNGAL DRUGS  •   Overview  •   Types of Fungal Infections         o Superficial         o Systemic    ...
o   Antibiotic Pharmacokinetics         o   Monitoring Therapy  •   Combination Therapy and Prophylactic Use  •   Bacteria...
•   Viral Infection Statistics  •   Description of Antivirals Products          o Nucleoside Analogs, Transcriptase Inhibi...
•   Pfizer  •   Roche  •   Schering-Plough Corporation  •   WyethAPPENDIX: LIST OF MAJOR PROVIDERSLIST OF EXHIBITSCHAPTER ...
•   Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2009 and      2013  •   Table 3-13: The World Marke...
•   Table 4-11: Currently Available Other Miscellaneous Antibiotics (Type, Brand,      and Manufacturer)  •   Table 4-12: ...
••   Table 5-5: Currently Available Nucleotide Analog Reverse Transcriptase    Inhibitors (Type, Brand, and Manufacturer)•...
•    •   Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading        Suppliers, 2009    •    •  ...
Upcoming SlideShare
Loading in …5
×

Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), The

1,417 views
1,337 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,417
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
21
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), The

  1. 1.    Get more info on this report!The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials andAntivirals)October 1, 2009The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugshave turned bacterial infections into treatable conditions rather than the life-threateningscourges they once were. But the effectiveness of many antibiotics is waningdramatically, as more and more types of bacteria become resistant to them.This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition.The report focuses on three key segments of treatment: • Antifungals (Allylamines, Azoles,Polyene Macrolides and Other Antifungals) • Antibacterials (Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Carbopenems, Miscellaneous) • Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors)For each category and each subsegment, current market and forecast is provided. Thereport covers both currently marketed and late stage development products.. Revenuesfor each segment were generated using dollar sales for each product.The report includes statistical information for infections by type worldwide, with specialemphasis on the U.S. and Europe. As part of its coverage the report provides: • Overview • Description of Products on the Market • Review of Products in Late Stage Development • Market Estimates and Forecasts • Competitive Analysis of Leading Providers • Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and Asia) • Market Share of Antifungal, Antibacterial and Antiviral Market
  2. 2. The information for this report was gathered using both primary and secondary researchincluding comprehensive research of secondary sources such as company literature,databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primarymethod of gathering information. For the purpose of this study Kalorama Informationconducted interviews with key industry officials, consultants, health care providers, andgovernment personnel. These sources were the primary basis in gathering informationspecifically relating to revenue and market share data presented in this report. Specificinterviews with pharmaceutical company representatives included marketing directors,division managers, and product representatives.Table of ContentsCHAPTER ONE: EXECUTIVE SUMMARY • Introduction • Scope and Methodology • Total Size and Growth of the Market • Issues and Trends Affecting Market • Leading CompetitorsCHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS • Overview • Introduction to Pathogens • Demographics of the World • Anti-Infective Drug Resistance o Antibiotic Abuse o Antibiotic Use in Agriculture o Resistance in Select Populations o Children o The Elderly o Compromised Individuals o Measures for Reducing Resistance o Antibiotic Cycling o Antibiotic Education o Screening Hospitalized patients • HIV Trends o Infection Rates o HIV and Women o Costs and Funding of HIV Treatment o Access to HIV/AIDS Treatment • Manufacturer and Marketer Trends o Trends in Partnerships and Alliances o Developers Trends o Trends in Rx-to-OTC Switches
  3. 3. CHAPTER THREE: ANTIFUNGAL DRUGS • Overview • Types of Fungal Infections o Superficial o Systemic o Histoplasmosis o Coccidioidomycosis o Blastomycosis o Fungal Infection Statistics o Fungal Infection Risk • Description of Antifungal Products o Systemic Antifungals o Allylamines o Azoles o Polyene Macrolides o Systemic Miscellaneous Antifungals o Topical Antifungals o Allylamines o Topical Azoles o Topical Polyene Macrolides o Topical Miscellaneous Antifungals • Market Overview • Total Market Size and Forecast • Antifungal Market by Product Type o Allylamines o Azoles o Polyene Macrolides o Other Antifungals Antifungal Market by Geographical Region • Market Analysis by Treated Condition • Competitive AnalysisCHAPTER FOUR: ANTIBACTERIAL DRUGS • Overview • Classification of Antibacterial Organisms • Antimicrobial Spectrum • Bacterial Resistance • Principles of Anti-bacterial Therapy o Infecting Organism o Antibiotic Sensitivity Testing o Site of Infection o Host Defenses and Organ Function
  4. 4. o Antibiotic Pharmacokinetics o Monitoring Therapy • Combination Therapy and Prophylactic Use • Bacterial Infection Statistics • Bacterial Infection Risk • Description of Antibacterial Products o Cephalosporins o Macrolides o Penicillins o Quinolones o Sulfonamides o Tetracyclines o Carbopenems o Systemic Miscellaneous Antibiotics Market Overview • Total Market Size and Forecast • Antibacterial Market by Product Type • Cephalosporins • Macrolides • Penicillins • Quinolones • Sulfonamides • Tetracyclines • Carbopenems • Other Products • Antibacterial Market by Geographical Region • Market Analysis by Treated Condition • Competitive Analysis • Leading ProductsCHAPTER FIVE: ANTIVIRAL DRUGS • Overview: Introduction to Viruses • Examples of Pathogenic Viruses • Virus Function and Life History • Replication in DNA Viruses • Replication of RNA Viruses • Replication in Retroviruses • Host Defenses Against Viruses • Viral Ploys to Invade Host Cells and Circumvent Host Responses o Invasion of Host Cells o Subversion of the Immune Response o Avoidance of Immune Detection and Attack by Killer Cells • HIV and AIDS
  5. 5. • Viral Infection Statistics • Description of Antivirals Products o Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors o Nucleoside Reverse Transcriptase Inhibitors o Combination Nucleoside Reverse Transcriptase Inhibitors o Nucleotide Analogue Reverse Transcriptase Inhibitors o Non-Nucleoside Reverse Transcriptase Inhibitors o Combination Non-Nucleoside Reverse Transcriptase Inhibitors o DNA Polymerase Inhibitors Protease Inhibitors • Other Antivirals • Market Overview • Total Market Size and Forecast o Antiviral Market by Product Type o Nucleoside Analogs o Protease Inhibitors o Other Antivirals o Antiviral Market by Geographical Region • Market Analysis by Treated Condition • Competitive Analysis • Leading ProductsCHAPTER SIX: MARKET SUMMARY • Total Market Size and Forecast • Market by SegmentCHAPTER SEVEN: CORPORATE PROFILES • Introduction • Abbott Laboratories • AstraZeneca/MedImmune • Bayer Schering Pharma AG • Bristol-Myers Squibb • Daiichi Sankyo • Gilead Sciences • GlaxoSmithKline • Johnson & Johnson Group • Merck & Co. • Novartis
  6. 6. • Pfizer • Roche • Schering-Plough Corporation • WyethAPPENDIX: LIST OF MAJOR PROVIDERSLIST OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY • Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2006-2013 • Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2009CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS • Table 2-1: Estimated World Population by Age and Geographical Region, 2009 • Figure 2-1: Estimated World Population by Age and Geographical Region, 2009 • Table 2-2: Worldwide HIV/AIDS Infections • Table 2-3: Women Living with HIV/AIDS, by Region 1990 to 2007 (Percent) • Table 2-4: AIDS Resource Needs (US$ billion), 2006-2008 • Table 2-5: Antiretroviral Access for HIV Infected Individuals by Region, 2005* • Table 2-6: Anti-Infective Drugs in Development by Developer • Table 2-7: Anti-infectives Ingredients Transferred from Rx-to-OTCCHAPTER THREE: ANTIFUNGAL DRUGS • Table 3-1: Estimated World and U.S. Incidence of Fungal Infections • Figure 3-1: Estimated World and U.S. Incidence of Leading Fungal Infections • Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009 • Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009 • Table 3-3: Systemic Allylamines • Table 3-4: Systemic Azoles • Table 3-5: Systemic Polyene Macrolides • Table 3-6: Systemic Miscellaneous Antifungals • Table 3-7: Topical Allylamines • Table 3-8: Topical Azoles • Table 3-9: Topical Polyene Macrolides • Table 3-10: Topical Miscellaneous Antifungals • Table 3-11: The World Market for Antifungal Drugs 2006-2013 • Figure 3-3: The World Market for Antifungal Drugs 2006-2013 • Table 3-12: Antifungal Drug Market by Type 2006-2013 • Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2006-2013
  7. 7. • Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2009 and 2013 • Table 3-13: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2006-2013 • Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2006-2013 • Table 3-14: World Antifungal Market Estimated Products Sales by Infection Type, Sales in Millions, 2009 • Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2009 • Table 3-15: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009 • Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers 2006-2009 • Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2009 • Table 3-16: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009 • Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009CHAPTER FOUR: ANTIBACTERIAL DRUGS • Table 4-1: Antibiotics with Difficult Penetration • Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections • Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections • Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009 • Figure 4-2: World Population at Risk for Serious Bacterial Infections Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009 • Table 4-4: Currently Available Cephalosporin Antibiotics (Type, Brand, and Manufacturer) • Table 4-5: Currently Available Macrolide Antibiotics (Type, Brand, and Manufacturer) • Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer) • Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer) • Table 4-7: Currently Available Quinolone Antibiotics (Type, Brand, and Manufacturer) • Table 4-8: Currently Available Sulfonamide Antibiotics (Type, Brand, and Manufacturer) • Table 4-9: Currently Available Tetracycline Antibiotics (Type, Brand, and Manufacturer) • Table 4-10: Currently Available Carbopenems (Type, Brand, and Manufacturer)
  8. 8. • Table 4-11: Currently Available Other Miscellaneous Antibiotics (Type, Brand, and Manufacturer) • Table 4-12: The World Market for Antibacterial Drugs 2006-2013 • Figure 4-3: The World Market for Antibacterial Drugs 2006-2013 • Table 4-13: Antibacterial Drug Market by Type 2006-2013 • Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type 2006- 2013 • Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2009 and 2013 • Table 4-14: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2006-2013 • Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2006-2013 • Table 4-17: World Antibacterial Market Estimated Products Sales by Infection Type • Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2009 • • Table 4-18: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009 • • Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2006-2009 • • Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2009 • • Table 4-19: World Market for Antibacterial Drugs Estimated Sales of Select Products 2006-2009 • • Figure 4-10: World Market for Antibacterial Drugs Estimated Sales of Top Ten Products 2006-2009CHAPTER FIVE: ANTIVIRAL DRUGS • Table 5-1: Host Cell Receptors • • Table 5-2: Estimated World and U.S. Incidence of Viral Infections • • Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections • • Table 5-3: Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer) • • Table 5-4: Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
  9. 9. •• Table 5-5: Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)•• Table 5-6: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)•• Table 5-7: Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)•• Table 5-8: Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)•• Table 5-9: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)•• Table 5-10: Currently Available Miscellaneous Antivirals (Type, Brand, and Manufacturer)•• Table 5-11: The World Market for Antiviral Drugs 2006-2013•• Figure 5-2: The World Market for Antiviral Drugs 2006-2013•• Table 5-12: Antiviral Drug Market by Type 2006-2013•• Figure 5-3: The World Market for Antiviral Drugs Revenues by Type 2006-2013•• Figure 5-4: The World Market for Antiviral Drugs Revenues by Type 2009 and 2013•• Table 5-13: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2006-2013•• Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2006-2013•• Table 5-14: World Antiviral Market Estimated Products Sales by Infection Type•• Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2009•• Table 5-15: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009•• Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2006-2009
  10. 10. • • Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2009 • • Table 5-16: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009 • • Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009CHAPTER SIX: MARKET SUMMARY • Table 6-1: The Global Market for Anti-Infectives by ProductSegment, 2006-2013 • • Figure 6-1: The World Market for Anti-Infective Drugs 2006-2013 • • Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2009 • • Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2013Available immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=2435380  US: 800.298.5699UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004 

×